

Effectiveness of convective water vapor energy therapy versus prostatic urethral lift for symptomatic benign prostatic hyperplasia: a systematic review and indirect comparison

Christopher T. Tallman, Paul F. Zantek, Natalia Hernandez, Ronald A. Morton Jr., Dongfeng Qi and Ricardo R. Gonzalez.* 2021 World Journal of Urology
<https://doi.org/10.1007/s00345-021-03595-8>

 Providing durable, long-lasting treatment to patients

Need for Medical and Surgical Retreatment*

1 in 4 
UroLift™ patients

1 in 9 
Rezūm™ Water Vapor Therapy patients

This means that over 4 years, **nearly 90%** of Rezūm patients were **free of retreatment**.

Treatment with Rezūm Therapy

Resulted in a **GREATER INCREASE** in urinary flow.** 

*In a post-hoc analysis of the Rezūm II and LIFT pivotal studies, 89.1% of men were BPH retreatment free 4 years after treatment with Rezūm Therapy and 75.4% of men were BPH retreatment free 4 years after treatment with UroLift Therapy.


**According to a post-hoc, indirect analysis of the Rezūm II and LIFT pivotal studies. Results are not directly comparable.

 Helping patients move forward with their lives


UroLift and Rezūm Therapy had **SIMILAR SAFETY PROFILES** 

Treatments did not differ significantly with respect to the odds of an AE [OR: 0.590; 95% CI: 0.190, 1.83] or serious AE [OR: 1.60; 95% CI: 0.0190, 134].

UroLift System



Rezūm Therapy



The UroLift System and Rezūm Therapy had **similar** subjective improvements in **symptoms versus blinded sham control (3 months)**. Subsequent study results showed sustained improvement through 5 years.^{1,2}

 Feeling confident in a product that offers assurances

Boston Scientific stands behind Rezūm Therapy. That's why we offer the **Rezūm Therapy Patient Assurance Program**, designed to increase your patients' confidence in Rezūm Therapy.



= **\$0**

Need a second BPH surgical intervention within 12 months?

Potential out-of-pocket expenses could be \$0.

See program details at www.Rezum.com/PatientAssurance

**Are you ready to Rezūm your practice?
Speak to a representative today.**

*Three authors of the study (PF Zantek, RA Morton and D Qi) are employees of Boston Scientific. RR Gonzalez is a consultant of Boston Scientific.

Potential risks associated with Rezūm Water Vapor Therapy include but are not limited to dysuria, hematuria, hematospermia, decrease in ejaculatory volume, suspected urinary tract infection (UTI), urinary frequency, and retention or urgency.

1. Roehrborn CG, Barkin J, Gange SN, et al. Five-year results of the prospective randomized controlled prostatic urethral LIFT study. *Can J Urol.* 2017 Jun;24(3):8802-13.
2. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of Rezūm water vapor thermal therapy for treatment of moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Urol.* 2021 Apr 19. Online ahead of print.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician. Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.

All trademarks are the property of their respective owners.
© 2021 Boston Scientific Corporation or its affiliates. All rights reserved.
URO-1020806-AA JUN 2021